Sage Therapeutics (NASDAQ:SAGE) Announces Quarterly Earnings Results

Sage Therapeutics (NASDAQ:SAGE) released its earnings results on Tuesday. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.52) by ($0.01), Briefing.com reports. The firm had revenue of $11.87 million during the quarter, compared to analyst estimates of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The firm’s revenue was up 337.1% on a year-over-year basis. During the same quarter last year, the business posted ($2.81) EPS.

Sage Therapeutics Trading Down 5.6 %

SAGE stock opened at $6.08 on Friday. The firm has a 50 day simple moving average of $7.44 and a 200-day simple moving average of $9.95. The company has a market capitalization of $371.93 million, a P/E ratio of -1.09 and a beta of 0.91. Sage Therapeutics has a twelve month low of $5.84 and a twelve month high of $28.26.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Robert W. Baird dropped their target price on Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 9th. StockNews.com downgraded shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Oppenheimer dropped their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Wednesday. JPMorgan Chase & Co. dropped their price objective on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, August 6th. Finally, HC Wainwright lowered their target price on Sage Therapeutics from $25.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday. Three investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $12.89.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.